<DOC>
	<DOCNO>NCT01042795</DOCNO>
	<brief_summary>The purpose study determine whether sutent ( sunitinib ) effective prevent tumor recurrence patient high risk bladder cancer previously chemotherapy cystectomy ( bladder removal ) . A 4 month supply drug give patient begin 2-3 month bladder removal . The patient follow 2 year .</brief_summary>
	<brief_title>Trial Adjuvant Sutent Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy Cystectomy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologic diagnosis bladder carcinoma ( &gt; 50 % urothelial carcinoma ) Prior treatment least one cycle platinbased neoadjuvant chemotherapy Prior treatment radical cystectomy reveal pT3NxM0 pTanyN+M0 ECOG performance status 01 ( Appendix 2 ) . No evidence metastasis within 4 week registration Adequate organ marrow function obtain within 14 day registration Severe uncontrolled acute chronic medical psychiatric condition Prior antiangiogenic therapy Prior pelvic radiation bladder cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>bladder neoplasm</keyword>
	<keyword>adjuvant treatment</keyword>
	<keyword>disease free survival</keyword>
	<keyword>Patients extravesical tumor ( pT2-4 , Nany , M0 pTanyN+M0 ) cystectomy platin-based neoadjuvant chemotherapy</keyword>
</DOC>